Samrna Biotech Co

The privately owned company is registered as SamRNA Co, Ltd. We own the patents of self-amplifying mRNA technology and aim to support mRNA medicine and its applications. Our goal is to facilitate and support the development of self-amplifying mRNA (samRNA) technologies. SamRNA is an artificially designed mRNA, of which the core mRNA sequence is flank with at least one RNA-dependent-RNA-polymerase (RdRp)-binding site in its 5’-end and 3’-end, respectively. The incorporated RdRp-binding sites can be recognized by coronaviral (e.g. COVID-19) and/or HCV replicase/RdRp enzymes, so as to activate RdRp-mediated amplification of the designed samRNA in vitro, ex vivo as well as in vivo. By simultaneous delivery of both samRNA and RdRp mRNA into targeted cells, samRNA can be used as an effective RNA/mRNA medicine or vaccine to reduce administration dose, prevent potential side-effects, and increase desired drug effects in the treated cells. We provide full patent protection for the mRNA medicines that we design for you. Our services include consulting, IP Licensing, and mRNA/ SamRNA design, and aim to expand to manufacture in the future.